Glen Harbor Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Glen Harbor Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$294K	Hold	3,652	–	–	0.01%	887
2019 Q2	$265K	Sell	3,652 -660	-15%	-$50.6K	0.01%	933
2019 Q1	$403K	Sell	4,312 -44	-1%	-$3.68K	0.01%	755
2018 Q4	$318K	Sell	4,356 -41,910	-91%	-$3.22M	0.01%	784
2018 Q3	$4.05M	Sell	46,266 -4,642	-9%	-$467K	0.08%	238
2018 Q2	$5.01M	Buy	50,908 +12,166	+31%	+$1.21M	0.11%	189
2018 Q1	$4.61M	Buy	+38,742	New	+$4.99M	0.1%	189

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Glen Harbor Capital Management's ALNY Position: Q3 2019 in Review

Glen Harbor Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2019 at 3,652 shares worth $294K. The position accounts for 0.01% of the portfolio, ranked #887.

Glen Harbor Capital Management first reported a position in ALNY in Q1 2018 and has held it in 7 quarters since. The position peaked at $5.01M in Q2 2018. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

Glen Harbor Capital Management held 3,652 shares of Alnylam Pharmaceuticals worth $294K as of Q3 2019.
Glen Harbor Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q3 2019.
Alnylam Pharmaceuticals made up 0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #887 holding.
Glen Harbor Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Glen Harbor Capital Management's Alnylam Pharmaceuticals position peaked at $5.01M in Q2 2018.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.